89 related articles for article (PubMed ID: 20131510)
1. [Efficiency of immunohistochemical study of high-molecular-weight cytokeratins (CKR-HMW) and p63 in prostate trepan biopsy specimens for establishing the diagnosis of adenocarcinoma].
Raskin GA
Arkh Patol; 2009; 71(6):48-9. PubMed ID: 20131510
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.
Weinstein MH; Signoretti S; Loda M
Mod Pathol; 2002 Dec; 15(12):1302-8. PubMed ID: 12481011
[TBL] [Abstract][Full Text] [Related]
3. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
4. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
Ali TZ; Epstein JI
Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
[TBL] [Abstract][Full Text] [Related]
5. Minimal adenocarcinoma in prostate needle biopsy tissue.
Thorson P; Humphrey PA
Am J Clin Pathol; 2000 Dec; 114(6):896-909. PubMed ID: 11338479
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations.
Shah RB; Kunju LP; Shen R; LeBlanc M; Zhou M; Rubin MA
Am J Clin Pathol; 2004 Oct; 122(4):517-23. PubMed ID: 15487448
[TBL] [Abstract][Full Text] [Related]
7. Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study.
Wang W; Sun X; Epstein JI
Am J Surg Pathol; 2008 Jun; 32(6):851-7. PubMed ID: 18408595
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical pitfalls in prostate pathology.
Brimo F; Epstein JI
Hum Pathol; 2012 Mar; 43(3):313-24. PubMed ID: 22325142
[TBL] [Abstract][Full Text] [Related]
9. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
11. [Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer].
Yu T; Zhu SX; Zheng S; Chen SP
Zhonghua Nan Ke Xue; 2007 Mar; 13(3):222-5. PubMed ID: 17393784
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens.
Epstein JI
Cancer; 1996 Jul; 78(2):350-6. PubMed ID: 8674016
[TBL] [Abstract][Full Text] [Related]
13. An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays.
Sanderson SO; Sebo TJ; Murphy LM; Neumann R; Slezak J; Cheville JC
Am J Clin Pathol; 2004 Feb; 121(2):220-5. PubMed ID: 14983935
[TBL] [Abstract][Full Text] [Related]
14. Distorted rectal tissue on prostate needle biopsy: a mimicker of prostate cancer.
Schowinsky JT; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):866-70. PubMed ID: 16819329
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
16. [Immunohistochemic staining for CK5/6 and P63 significance in prostate premalignant lesions and adenocarcinoma].
Marin LV; Ferariu D; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2010; 114(3):818-22. PubMed ID: 21243809
[TBL] [Abstract][Full Text] [Related]
17. [Clinical value of CK34BE12 combining the expression of protein P53 gene and prostate specific antigen for the differential diagnosis of prostate carcinoma].
Gu XJ; Lu JL; Lai RS; Zhang YD; Zhang P; Lu ZJ; Zhu QY
Zhonghua Nan Ke Xue; 2006 Apr; 12(4):340-2. PubMed ID: 16683569
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
19. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
Osunkoya AO; Hansel DE; Sun X; Netto GJ; Epstein JI
Am J Surg Pathol; 2008 Mar; 32(3):461-7. PubMed ID: 18300803
[TBL] [Abstract][Full Text] [Related]
20. Formalin fixation and immunoreactivity in prostate cancer and benign prostatic tissues.
Jaraj SJ; Egevad L
APMIS; 2010 May; 118(5):383-8. PubMed ID: 20477814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
